Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: PROHANCE

« Back to Dashboard
Prohance is a drug marketed by Bracco and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug.

This drug has ten patent family members in five countries.

The generic ingredient in PROHANCE is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.

Summary for Tradename: PROHANCE

Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: see list7

Pharmacology for Tradename: PROHANCE

Clinical Trials for: PROHANCE

Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Status: Completed Condition: Brain Disease

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Status: Completed Condition: Brain Metastases

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Status: Completed Condition: Diagnostic Imaging; Central Nervous System Diseases

Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
Status: Completed Condition: Renal Insufficiency

Baseline Cortical Haemodynamics in MS
Status: Not yet recruiting Condition: Multiple Sclerosis

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
Status: Recruiting Condition: Adult Brain Glioblastoma

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Completed Condition: Coronary Artery Disease; Type 1 Diabetes Mellitus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco
PROHANCE
gadoteridol
INJECTABLE;INJECTION020131-001Nov 16, 1992RXYes5,846,519<disabled> <disabled>
Bracco
PROHANCE MULTIPACK
gadoteridol
INJECTABLE;INJECTION021489-001Oct 9, 2003RXYes5,846,519<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PROHANCE

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco
PROHANCE
gadoteridol
INJECTABLE;INJECTION020131-001Nov 16, 19924,885,363<disabled>
Bracco
PROHANCE
gadoteridol
INJECTABLE;INJECTION020131-001Nov 16, 19925,474,756<disabled>
Bracco
PROHANCE
gadoteridol
INJECTABLE;INJECTION020131-001Nov 16, 19925,846,519<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: PROHANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,885,363 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs<disabled in preview>
5,474,756 Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs<disabled in preview>
5,674,470 Method for imaging mammalian tissue using 1-substituted- 4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PROHANCE

Country Document Number Publication Date
Canada1296715Mar 03, 1992
European Patent Office0292689Jul 31, 1991
Japan2604796Apr 30, 1997
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc